1. Home ›
  2. Labs ›
  3. Lu Lab ›
  4. Publications

Publications

Articles published in peer-reviewed journals

View the updated list of Lu lab's publications with link to PubMed: https://www.ncbi.nlm.nih.gov/myncbi/14A325uGbh1Ab/bibliography/public/

2024
2023

Feel free to download PDF reprint from this link: https://www.science.org/stoken/author-tokens/ST-1068/full

2022
2021
2020
2019
  • Wang Q, Guldner IH, Golomb SM, Sun L, Harris JA, Lu X, Zhang S. Single-cell profiling guided combinatorial immunotherapy for fast-evolving CDK4/6 inhibitor-resistant HER2-positive breast cancer. Nat Commun. 2019 Aug 23;10(1):3817. doi: 10.1038/s41467-019-11729-1. PubMed PMID: 31444334; PubMed Central PMCID: PMC6707314.
  • Cheng X, Jin Z, Ji X, Shen X, Feng H, Morgenlander W, Ou B, Wu H, Gao H, Ye F, Zhang Y, Peng Y, Liang J, Jiang Y, Zhang T, Qiu W, Lu X#, Zhao R#. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB. Int J Cancer. 2019 Jul 1;145(1):179-191. doi: 10.1002/ijc.32071. Epub 2019 Jan 28. PubMed PMID: 30650178.
  • Feng S, Wen X, Lu X#. Nitropeptide Profiling and Identification Illustrated by Angiotensin II. J Vis Exp. 2019 Jun 16;(148). doi: 10.3791/59391. PubMed PMID: 31259896.
  • Zhang L, Shen H, Gong Y, Pang X, Yi M, Guo L, Li J, Arroyo S, Lu X, Ovchinnikov S, Cheng G, Liu X, Jiang X, Feng S, Deng H. Development of a dual-functional conjugate of antigenic peptide and Fc-III mimetics (DCAF) for targeted antibody blocking. Chem Sci. 2019 Mar 21;10(11):3271-3280. doi: 10.1039/c8sc05273e. eCollection 2019 Mar 21. PubMed PMID: 30996912; PubMed Central PMCID: PMC6429600.
  • Feng S, Wen X, Lu X. Nitropeptide Profiling and Identification Illustrated by Angiotensin II. J Vis Exp. 2019, In press
2018
  • Feng S, Cheng X, Zhang L, Lu X, Chaudhary S, Teng R, Frederickson C, Champion MM, Zhao R, Cheng L, Gong Y, Deng H, Lu X. Myeloid-Derived Suppressor Cells Inhibit T Cell Activation through Nitrating LCK in Mouse Cancers. Proc. Natl. Acad. Sci., 2018; 115(40):10094-10099. [PMID: 30232256]
  • Lu X*, Pan X*, Wu CJ, Zhao D, Feng S, Zang Y, Lee R, Khadka S, Amin SB, Jin EJ, Shang X, Deng P, Luo Y, Morgenlander WR, Weinrich J, Lu X, Jiang S, Chang Q, Navone NM, Troncoso P, DePinho RA, Wang YA. An In Vivo Screen Identifies PYGO2 as a Driver for Metastatic Prostate Cancer. Cancer Research. 2018; 78(14):3823-3833. [PMID: 29769196]
  • Moreira D, Adamus T, Zhao X, Su YL, Zhang Z, White SV, Swiderski P, Lu X, DePinho RA, Pal SK, Kortylewski M. STAT3 Inhibition Combined with CpG Immunostimulation Activates Antitumor Immunity to Eradicate Genetically Distinct Castration-Resistant Prostate Cancers. Clin Cancer Res. 2018 Dec 1;24(23):5948-5962.
2016-2017
  • Xin Lu, Eun-Jung Jin, Xi Cheng, Shan Feng, Xiaoying Shang, Pingna Deng, Shan Jiang, Qing Chang, Sharif Rahmy, Seema Chaudhary, Xuemin Lu, Y. Alan Wang, Ronald A. DePinho. Opposing Roles of TGFβ and BMP Signaling in Prostate Cancer Development. Genes & Development. 2017; 31(23-24):2337-2342.
  • Lu X, Horner JW, Paul E, Shang X, Troncoso P, Deng P, Jiang S, Chang Q, Varma A, Han JW, Spring DJ, Sharma P, Zebala JA, Maeda DY, Wang YA, and DePinho RA. Effective Combinatorial Immunotherapy for Metastatic Castration-Resistant Prostate Cancer. Nature. 2017; 543:728-732. Editorial by: Nat Rev Urol. 2017 Mar 21. doi: 10.1038/nrurol.2017.44. Cancer Discov. 2017 Mar 31. doi: 10.1158/2159-8290.CD-RW2017-064.
  • Zhao D, Lu X, Wang G, Lan Z, Liao W, Li J, Liang X, Chen JR, Shah S, Shang X, Tang M, Deng P, Dey P, Chakravarti D, Chen P, Spring DJ, Navone NM, Troncoso P, Zhang J, Wang YA, DePinho RA. Synthetic essentiality of chromatin remodelling factor CHD1 in PTEN-deficient cancer. Nature. 2017;542:484-488.
  • Hu B, Wang Q, Wang YA, Hua S, Sauvé CG, Ong D, Lan ZD, Chang Q, Ho YW, Monasterio MM, Lu X, Zhong Y, Zhang J, Deng P, Tan Z, Wang G, Liao WT, Corley LJ, Yan H, Zhang J, You Y, Liu N, Cai L, Finocchiaro G, Phillips JJ, Berger MS, Spring DJ, Hu J, Sulman EP, Fuller GN, Chin L, Verhaak RG, DePinho RA. Epigenetic Activation of WNT5A Drives Glioblastoma Stem Cell Differentiation and Invasive Growth. Cell. 2016; 167(5):1281-1295
  • Wang G*, Lu X*, Dey P, Deng P, Wu C, Jiang S, Fang Z, Zhao K, Konaparthi R, Hua S, Zhang J, Tapia E,Kapoor A, Wu C, Patel N, Guo Z, Ramamoorthy V, Tieu T, Heffernan T, Zhao D, Shang X, Khadka S, Hou P, Hu B, Jin E, Yao W, Pan X, Ding Z, Shi Y, Li L, Chang Q, Troncoso P, Logothetis C, McArthur M, Chin L, Wang YA, DePinho RA. Targeting YAP-dependent MDSC infiltration impairs tumor progression. Cancer Discovery. 2016 Jan;6(1):80-95. (*Co-first authors with equal contribution)
2012-2014
  • Wan L, Lu X, Yuan S, Wei Y, Guo F, Shen M, Yuan M, Chakrabarti R, Hua Y, Smith HA, Blanco MA, Chekmareva M, Wu H, Bronson RT, Haffty BG, Xin Y, Kang Y. MTDH-SND1 Interaction Is Crucial for Expansion and Activity of Tumor-Initiating Cells in Diverse Oncogene- and Carcinogen-Induced Mammary Tumors. Cancer Cell. 2014: 26(1):92-105
  • Lu X*, Agasti S*, Vinegoni C, Waterman P, DePinho RA, Weissleder R. Optochemogenetics (OCG) allows more precise control of genetic engineering in mice with CreER regulators. Bioconjugate Chemistry. 2012: 23(9):1945-51. US Patent # 20150093365. Issued 4/2/2015
  • Ding Z, Wu CJ, Jaskelioff M, Ivanova E, Kost-Alimova M, Protopopov A, Chu GC, Wang G, Lu X, Labrot ES, Hu J, Wang W, Xiao Y, Zhang H, Zhang J, Zhang J, Gan B, Perry SR, Jiang S, Li L, Horner JW, Wang YA, Chin L, DePinho RA. Telomerase reactivation following telomere dysfunction yields murine prostate tumors with bone metastases. Cell. 2012; 148:896-907.
  • Liang Y, Wu H, Lei R, Chong RA, Wei Y, Lu X, Tagkopoulos I, Kung SY, Yang Q, Hu G, Kang Y. Transcriptional network analysis identifies BACH1 as a master regulator of breast cancer bone metastasis. J Biol Chem. 2012;287(40):33533-44
2005-2011
  • Lu X, Mu E, Wei Y, Riethdorf S, Yang Q, Yuan M, Yan J, Hua Y, Tiede B, Lu X, Haffty B, Pantel K, Massagué J, and Kang Y. VCAM-1 promotes osteolytic expansion of indolent bone micrometastasis of breast cancer by engaging α4β1-positive osteoclast progenitors. Cancer Cell. 2011; 20:701-714. (Featured Article) Most downloaded paper in Dec, 2011.Editorial by: Hynes RO. (2011) Cancer Cell, 20:689-690. Seton-Rogers S. (2011) Nature Reviews Cancer, 12: 920. Haas MJ. (2012) SciBX, 5(2):1-2.
  • Zhang X, Tamasi J, Lu X, Zhu J, Chen H, Tian X, Lee TC, Threadgill DW, Kream BE, Kang Y, Partridge NC, Qin L. Epidermal growth factor receptor plays an anabolic role in bone metabolism in vivo. J Bone Miner Res. 2011; 26(5):1022-34
  • Lu X, and Kang Y. (2010) Hypoxia and hypoxia-inducible factors (HIFs): master regulators of metastasis. Clin. Cancer Res. 2010; 16:5928-35
  • Lu X, Lu X, and Kang Y. Organ-specific enhancement of metastasis by spontaneous ploidy duplication and cell size enlargement. Cell Res. 2010; 20:1012–1022.
  • Lu X, Yan C, Yuan M, Wei Y, Hu G, and Kang Y. In vivo dynamics and distinct functions of hypoxia in primary tumor growth and organotropic metastasis of breast cancer. Cancer Res. 2010; 70: 3905-3914
  • Lu X*, Bennet B*, Mu E*, Rabinowitz J, and Kang Y. Metabolomic profiling reveals a two-step metabolic progression model of metastatic breast cancer. J. Biol. Chem. 2010; 285: 9317-9321
  • Lu X, and Kang Y. Epidermal growth factor signaling and bone metastasis. Br. J. Cancer. 2010; 102: 457-461.
  • Lu X, and Kang Y. Metalloproteinases and osteoblast EGFR signaling in osteolytic bone metastasis of breast cancer. Cell Cycle. 2009; 8: 3804-3805.
  • Lu X, and Kang Y. Cell fusion as a hidden force in tumor progression. Cancer Res. 2009; 69: 8536-8539.
  • Lu X, and Kang Y. Chemokine (C-C Motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J. Biol. Chem. 2009; 284: 29087-29096.
  • Lu X, Wang Q, Hu G, Van Poznak C, Fleisher M, Reiss M, Massagué J, and Kang Y. ADAMTS1 and MMP1 proteolytically engage EGF-like ligands in an osteolytic signaling cascade for bone metastasis. Genes & Dev. 2009; 23:1882-1894. (Cover highlight) Editorial by: Guise TA. (2009) Gens & Dev., 23:2117-23.
  • Korpal M, Yan J, Lu X, Xu S, Lerit DA, and Kang Y. Imaging transforming growth factora signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 2009; 15:960-966.
  • Lu X, and Kang Y. Efficient acquisition of dual metastasis organotropism to bone and lung through stable spontaneous fusion between MDA-MB-231 variants. Proc. Natl. Acad. Sci. 2009; 106:9385-9390.
  • Lu X, and Kang Y. Organotropism of Breast Cancer Metastasis. J. Mammary. Gland. Biol. Neoplasia. 2007; 12:153-162.
  • Lu X, and Kang Y. Discovery of bone metastasis genes by functional genomics. Pharmacol. Discov. Dec, 2005:1-4.
Book Chapter
  • Lu X, and Kang Y. Cell fusion hypothesis of the cancer stem cell. In: Dittmar T and Zänker K (eds.) Cell Fusion in Health and Disease, Advances in Experimental Medicine and Biology. 2011; 714:129-40.